Trait Openness and serotonin 2A receptors in healthy volunteers: A positron emission tomography study
Dea Siggaard Stenbæk, Sara Kristiansen, Daniel Burmester, M. Madsen, Vibe G. Frøkjær, Gitte M. Knudsen, Patrick M. Fisher
Human Brain Mapping January 11, 2019 DOI: 10.1002/hbm.24511 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Observational cohort Peer reviewed |
|---|---|
| Sample size | 159 |
| Population | Healthy individuals (53 females) |
| Topics | Serotonin |
| Keywords | Positron emission tomography Trait Openness to experience Receptor |
| Citations | 11 |
| Key findings | No significant association between neocortical 5-HT2A receptor binding and trait Openness in healthy individuals. |
Abstract
Abstract Recent research found lasting increases in personality trait Openness in healthy individuals and patients after administration of the serotonin 2A receptor (5‐HT 2A R) agonist psilocybin. However, no studies have investigated whether 5‐HT 2A R availability as imaged using positron emission tomography (PET) is associated with this trait. In 159 healthy individuals (53 females), the association between 5‐HT 2A R binding in neocortex imaged with [ 18 F]altanserin or [ 11 C]Cimbi‐36 PET and personality trait Openness was investigated using linear regression models. In these models the influence of sex on the association was also investigated. Trait Openness was assessed with the NEO Personality Inventory‐Revised. No significant associations between neocortical 5‐HT 2A R binding and trait Openness were found for [ 18 F]altanserin ( p = 0.5) or [ 11 C]Cimbi‐36 ( p = 0.8). Pooling the data in a combined model did not substantially change our results ( p = 0.4). No significant interactions with sex were found ( p > 0.35). Our results indicate that differences in 5‐HT 2A R availability are not related to variations in trait Openness in healthy individuals. Although stimulation of the 5‐HT 2A R with compounds such as psilocybin may contribute to long‐term changes in trait Openness, there is no evidence in favor of an association between 5‐HT 2A R and trait Openness.
Comparable studies
Other observational and cohort studies on serotonin, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels Healthy volunteers | 2019 | Observational cohort | n = 8 |
| Memory impairment in abstinent MDMA ("Ecstasy") users Abstinent MDMA users | 1998 | Observational cohort | |
| Dynamic coupling of whole-brain neuronal and neurotransmitter systems Healthy humans | 2020 | Observational study | |
| The Serotonin System and Spiritual Experiences Normal male subjects, ages 20-45 years | 2003 | Observational cohort | n = 15 |
| Whole-Brain Multimodal Neuroimaging Model Using Serotonin Receptor Maps Explains Non-linear Functional Effects of LSD. Healthy human participants | 2018 | Observational study with computational modeling |
Citations in the library
Cited by 5
- A single psilocybin dose is associated with long-term increased mindfulness, preceded by a proportional change in neocortical 5-HT2A receptor binding European Neuropsychopharmacology March 4, 2020
- Psychedelic Therapy's Transdiagnostic Effects: A Research Domain Criteria (RDoC) Perspective Frontiers in Psychiatry December 17, 2021
- Molecular and Functional Imaging Studies of Psychedelic Drug Action in Animals and Humans Molecules April 22, 2021
- Differences in personality, cognitive abilities, illicit drug use, and white matter structural integrity between hallucinogen users and matched controls Research Square April 20, 2022
- Avaliação das possíveis interações entre o canabidiol e a ayahuasca em voluntários saudáveis: um estudo randomizado, duplo-cego e controlado com placebo November 27, 2020
Cites 20
- Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial Journal of Psychopharmacology November 30, 2016
- Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial Journal of Psychopharmacology November 30, 2016
- Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance Psychopharmacology July 7, 2006
- Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. The Lancet Psychiatry May 17, 2016
- Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer Archives of General Psychiatry September 7, 2010
and 15 more in the library